Results 11 to 20 of about 2,002 (144)

A case of indolent systemic mastocytosis responding to treatment with Avapritinib [PDF]

Clinical Case Reports (discontinued), 2023
Key Clinical Message Low dose Avapritinib is a new medication that is a potential treatment option not just for advanced systemic mastocytosis, but also for the indolent form.
Terrence Sun
exaly   +5 more sources

Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial [PDF]

Journal of Allergy and Clinical Immunology: Global
Background: Indolent systemic mastocytosis is a clonal mast cell disease that results in an increase in mast cells in the skin, bone marrow, and other organ systems.
Hirsh D Komarow, Dean D Metcalfe
exaly   +6 more sources

Chronic Anaphylaxis With Indolent Systemic Mastocytosis: A Case Report [PDF]

Case Reports in Hematology
Systemic mastocytosis is a rare, clonal mast cell disease neoplasm driven by the KIT D816V mutation in greater than 95% of cases. The complex clinical presentation of systemic mastocytosis can make diagnosis challenging.
Sarah Worth, Tracy I. George, Daniel J. Shaheen, Maria Roche, Pankit Vachhani   +4 more
doaj   +4 more sources

Efficacy of Omalizumab in Indolent Systemic Mastocytosis [PDF]

Case Reports in Hematology, 2019
Background. Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs.
Calum Slapnicar, Martina Trinkaus, Lisa Hicks, Peter Vadas   +3 more
doaj   +6 more sources

DNA methylation profile in patients with indolent systemic mastocytosis [PDF]

Clinical and Translational Allergy, 2021
Background Mastocytosis is a clinically heterogeneous, usually acquired disease of the mast cells with a survival time that depends on the onset of the disease and ranges from skin‐limited to systemic disease, including indolent and more aggressive ...
Aleksandra Górska, Ewa Jabłońska, Edyta Reszka, Marek Niedoszytko, Magdalena Lange, Marta Gruchała‐Niedoszytko, Justyna Jarczak, Dominik Strapagiel, Magdalena Górska‐Ponikowska, Paulina Bastian, Iwona Pelikant‐Małecka, Leszek Kalinowski, Bogusław Nedoszytko   +12 more
doaj   +5 more sources

Delayed diagnosis of adult indolent systemic mastocytosis [PDF]

Dermatology Reports, 2014
Systemic mastocytosis (SM) is a rare, heterogeneous disorder characterized by infiltration and accumulation of mast cells within multiple organs, most commonly the skin. Given the rarity of the disease and the fact that many of its symptoms are shared by
Carsten Sauer Mikkelsen, Andrew Nybo, Kristian Bakke Arvesen, Johan Holk-Poulsen   +3 more
doaj   +5 more sources

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis [PDF]

World Allergy Organization Journal
Background: Patients with indolent systemic mastocytosis (ISM), a clonal mast cell disease primarily driven by the KIT D816V mutation, often have lifelong debilitating symptoms.
Thanai Pongdee, MD, Mariana Castells, MD, PhD, Cem Akin, MD, Ingunn Dybedal, MD, PhD, Jason Gotlib, MD, Jens Peter Panse, MD, Ivan Alvarez-Twose, MD, PhD, Cristina Morales Cabeza, MD, Sonia Cerquozzi, MD, FRCPC, Peter Vadas, MD, Vidushi Swarup, MS, Pankit Vachhani, MD, Friederike Wortmann, MD, Cecilia Arana Yi, MD, Ilda Bidollari, MD, Kate Newberry, PhD, Daniel Shaheen, PharmD, Karin Hartmann, MD   +17 more
doaj   +4 more sources

Diagnosis of indolent systemic mastocytosis in a patient with “seborrheic keratosis” [PDF]

Hematology, Transfusion and Cell Therapy, 2022
Habib Moshref Razavi, Samuel Krikler
doaj   +5 more sources

Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case Report [PDF]

Case Reports in Oncology, 2023
Mastocytosis is a heterogeneous group of disorders in which mast cells exhibit clonal proliferation that infiltrates one or more organs. In cutaneous mastocytosis, the mast cells infiltrate the skin only, whereas systemic mastocytosis is diagnosed when ...
Awni Alshurafa, Mohammad Abu-Tineh, Feryal A. Ibrahim, Mahir Petkar, Mohamed A. Yassin   +4 more
doaj   +2 more sources

TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS

Mediterranean Journal of Hematology and Infectious Diseases, 2022
Management of Indolent and Smoldering SM is focused on preventing anaphylactic reactions, identifying and avoiding symptom triggers. Skin and gastrointestinal symptoms are managed with H1- and H2-antihistamines.
Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo   +2 more
doaj   +4 more sources